Cyclosporine

Generic Name: Cyclosporine

Brand Names: Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis

Drug Type: Small Molecule

Chemical Formula: C_₆₂H_₁₁₁N_₁₁O_₁₂

CAS Number: 59865-13-3

Unique Ingredient Identifier: 83HN0GTJ6D

Background: Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novar...

Indication: Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine ca...

Associated Conditions: Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 1

Withdrawn

Conditions: Leukemia

First Posted Date: 2003-11-24

Last Posted Date: 2012-11-19

Lead Sponsor: Columbia University

Registration Number: NCT00002761

Peripheral Stem Cell Transplantation Followed By Infusion of White Blood Cells in Treating Patients With AIDS-Related Lymphoma

Phase 2

Withdrawn

Conditions: Lymphoma

First Posted Date: 2003-10-21

Last Posted Date: 2016-02-03

Lead Sponsor: AIDS Malignancy Consortium

Registration Number: NCT00024128

Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-10-07

Last Posted Date: 2014-02-20

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 350

Registration Number: NCT00070174

Locations: 🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸
St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸
All Children's Hospital, St. Petersburg, Florida, United States

and more 145 locations

Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: aldesleukin
Biological: filgrastim
Biological: recombinant interferon gamma
Drug: carmustine
Drug: cyclosporine
Drug: cytarabine
Drug: etoposide
Drug: melphalan
Procedure: autologous bone marrow transplantation
Procedure: bone marrow ablation with stem cell support
Procedure: peripheral blood stem cell transplantation

First Posted Date: 2003-10-07

Last Posted Date: 2013-10-17

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 24

Registration Number: NCT00070187

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Children's Hospital of Minnesota - Minneapolis, Minneapolis, Minnesota, United States

and more 60 locations

Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma

Phase 2

Terminated

Conditions: Lymphoma

Interventions: Drug: cyclosporine

First Posted Date: 2003-10-07

Last Posted Date: 2023-06-29

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 4

Registration Number: NCT00070291

Locations: 🇺🇸
Hematology Oncology Associates of Illinois - Berwyn, Berwyn, Illinois, United States
🇺🇸
Hematology Oncology Associates - Skokie, Skokie, Illinois, United States
🇺🇸
Mercy Medical Center - Sioux City, Sioux City, Iowa, United States

and more 20 locations

Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

Not Applicable

Completed

Conditions: Lymphoma
Myelodysplastic/Myeloproliferative Diseases
Multiple Myeloma and Plasma Cell Neoplasm
Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2003-09-11

Last Posted Date: 2020-07-27

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 10

Registration Number: NCT00068523

Locations: 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

Phase 2

Terminated

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Myelodysplastic/Myeloproliferative Diseases

First Posted Date: 2003-08-07

Last Posted Date: 2013-05-01

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 51

Registration Number: NCT00066417

Locations: 🇺🇸
NIH - Warren Grant Magnuson Clinical Center, Bethesda, Maryland, United States

S0301 Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-08-07

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 69

Registration Number: NCT00066794

Locations: 🇺🇸
St. Luke's Mountain States Tumor Institute - Boise, Boise, Idaho, United States
🇺🇸
Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield, Michigan, United States
🇺🇸
Munson Medical Center, Traverse City, Michigan, United States

and more 94 locations

Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia

Phase 2

Completed

Conditions: Aplastic Anemia

Interventions: Drug: r-ATG
Drug: Campath-1H
Drug: CsA

First Posted Date: 2003-07-21

Last Posted Date: 2021-07-21

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 54

Registration Number: NCT00065260

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Radiation: iodine I 131 monoclonal antibody BC8
Drug: busulfan
Drug: cyclophosphamide
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: peripheral blood stem cell transplantation
Drug: cyclosporine
Drug: methotrexate
Other: laboratory biomarker analysis

First Posted Date: 2003-07-09

Last Posted Date: 2017-08-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00005940

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
🇺🇸
Pacific Northwest National Laboratory, Richland, Washington, United States
🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy